Ulrich Jager | EHA 2018 | Potential causes of aggressive B-cell lymphomas under JAK1/2 inhibition

Why should we use checkpoint inhibitors with CAR-T therapy in DLBCL?Подробнее

How will the sequencing of treatments for DLBCL change in the future?Подробнее

Prof. Ulrich Jager | ASH 2017 | Personalisation in DLBCLПодробнее

Simon Rule | EHA 2018 | What are the key findings of the acalabrutinib study in patients with WM?Подробнее

Prof. Ulrich Jäger: Durvalumab with R-CHOP or len in DLBCL - ICML 2017Подробнее

What is LYMPHOMA & How to Stage it!Подробнее

Should we treat high-risk DLBCL differently?Подробнее

IG rearrangement, JAK1/2 inhibition and aggressive B-cell lymphoma development...Подробнее

Ulrich Jäger | T2EVOLVE TalksПодробнее

Driving the CAR-T: bumps in the roadПодробнее

The next generation of novel agents in development for aggressive B-cell lymphomaПодробнее

Bispecific antibodies for R/R aggressive B-cell lymphomasПодробнее

EHA 18: Rituximab for b-cell lymphoma and EHA overviewПодробнее

Diffuse large B-cell lymphoma lymphoma: Finding the best partner for durvalumabПодробнее

The importance of lymphodepletion, an undervalued component of the CAR-T therapy cycleПодробнее

Martin Dreyling | EHA 2018 | Overview of EHA presentations in indolent lymphomaПодробнее

BTKI inhibitors in the treatment of B-cell lymphoma - Deborah Stephens sessionПодробнее

What was new in aggressive NHL at ASCO and EHA 2020?Подробнее